Compare Stocks: GRTS, CALC, INTS, and QNRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$2.17 -1.4%	$3.59	$2.00 ▼ $36.00	$14.82M	0.83	89,031 shs	94,119 shs
GRTS Gritstone bio	$0.03	$0.35	$0.03 ▼ $3.17	$3.50M	0.49	7.01 million shs	N/A
INTS Intensity Therapeutics	$4.10 +2.5%	$4.40	$3.51 ▼ $43.50	$13.39M	2.76	35,959 shs	4,451 shs
QNRX Quoin Pharmaceuticals	$7.26 -7.8%	$4.96	$3.25 ▼ $41.80	$14.58M	1.51	1.65 million shs	78,713 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	0.00%	-6.55%	-39.04%	-59.06%	-86.52%
GRTS Gritstone bio	0.00%	0.00%	0.00%	0.00%	0.00%
INTS Intensity Therapeutics	0.00%	-3.53%	-3.53%	+8.75%	-39.03%
QNRX Quoin Pharmaceuticals	0.00%	+18.63%	+58.86%	+61.69%	-5.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$2.17 -1.4%	$3.59	$2.00 ▼ $36.00	$14.82M	0.83	89,031 shs	94,119 shs
GRTS Gritstone bio	$0.03	$0.35	$0.03 ▼ $3.17	$3.50M	0.49	7.01 million shs	N/A
INTS Intensity Therapeutics	$4.10 +2.5%	$4.40	$3.51 ▼ $43.50	$13.39M	2.76	35,959 shs	4,451 shs
QNRX Quoin Pharmaceuticals	$7.26 -7.8%	$4.96	$3.25 ▼ $41.80	$14.58M	1.51	1.65 million shs	78,713 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	0.00%	-6.55%	-39.04%	-59.06%	-86.52%
GRTS Gritstone bio	0.00%	0.00%	0.00%	0.00%	0.00%
INTS Intensity Therapeutics	0.00%	-3.53%	-3.53%	+8.75%	-39.03%
QNRX Quoin Pharmaceuticals	0.00%	+18.63%	+58.86%	+61.69%	-5.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	2.20	Hold	$50.00	2,204.15% Upside
GRTS Gritstone bio	0.00	N/A	N/A	N/A
INTS Intensity Therapeutics	2.80	Moderate Buy	$7.00	70.73% Upside
QNRX Quoin Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest GRTS, CALC, INTS, and QNRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	CALC CalciMedica	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/18/2026	INTS Intensity Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $7.00
8/13/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CALC CalciMedica	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/11/2026	INTS Intensity Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/29/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/21/2026	INTS Intensity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/20/2026	QNRX Quoin Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	$0.81 per share	N/A
GRTS Gritstone bio	$496K	7.05	N/A	N/A	$0.54 per share	0.06
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	$2.82 per share	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$1.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$29.56M	-$6.80	N/A	N/A	N/A	N/A	-863.40%	-155.24%	11/11/2026 (Estimated)
GRTS Gritstone bio	-$138.49M	-$1.24	N/A	N/A	N/A	-910.50%	-328.51%	-82.53%	N/A
INTS Intensity Therapeutics	-$11.61M	-$3.57	N/A	N/A	N/A	N/A	-116.61%	-94.01%	11/5/2026 (Estimated)
QNRX Quoin Pharmaceuticals	-$15.81M	-$25.18	N/A	N/A	N/A	N/A	-489.57%	-221.17%	11/5/2026 (Estimated)

Latest GRTS, CALC, INTS, and QNRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	QNRX Quoin Pharmaceuticals	-$1.61	-$1.90	-$0.29	-$1.90	N/A	N/A
8/11/2026	Q2 2026	CALC CalciMedica	-$1.4250	-$0.45	+$0.9750	-$2.25	N/A	N/A
8/11/2026	Q2 2026	INTS Intensity Therapeutics	-$0.8725	-$1.11	-$0.2375	-$1.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
GRTS Gritstone bio	N/A	N/A	N/A	N/A	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	1.67	5.58	5.58
GRTS Gritstone bio	1.83	2.54	2.54
INTS Intensity Therapeutics	0.01	5.00	5.00
QNRX Quoin Pharmaceuticals	N/A	1.76	1.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
GRTS Gritstone bio	48.46%
INTS Intensity Therapeutics	3.74%
QNRX Quoin Pharmaceuticals	8.63%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	28.25%
GRTS Gritstone bio	4.61%
INTS Intensity Therapeutics	7.60%
QNRX Quoin Pharmaceuticals	11.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	30	6.83 million	4.90 million	No Data
GRTS Gritstone bio	190	108.57 million	111.84 million	No Data
INTS Intensity Therapeutics	2,021	3.26 million	3.02 million	Not Optionable
QNRX Quoin Pharmaceuticals	4	2.01 million	1.78 million	Not Optionable

GRTS, CALC, INTS, and QNRX Headlines

Recent News About These Companies

Research Analysts Set Expectations for QNRX FY2026 Earnings

September 4 at 1:13 AM | americanbankingnews.com

Insider Buying: Quoin Pharmaceuticals (NASDAQ:QNRX) Director Acquires $29,992.48 in Stock

September 2, 2026 | insidertrades.com

Quoin Pharma raises up to $50M for rare disease development

August 29, 2026 | thepharmaletter.comT

Quoin Pharma Surges 45% In Pre-Market On Positive QRX003 Data And $50M Private Placement

August 28, 2026 | rttnews.com

Quoin Pharmaceuticals stock surges Friday: What's happening?

August 28, 2026 | msn.com

Quoin Pharma Reports Positive Interim Data From Ongoing Phase 2/3 Study Of QRX003

August 28, 2026 | rttnews.com

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

August 28, 2026 | globenewswire.com

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

August 28, 2026 | globenewswire.com

QNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization

August 27, 2026 | finance.yahoo.com

Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 14, 2026 | globenewswire.com

Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on ...

August 7, 2026 | caledonianrecord.comC

Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026

August 7, 2026 | globenewswire.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

July 9, 2026 | finanznachrichten.de

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

July 9, 2026 | globenewswire.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

June 30, 2026 | finanznachrichten.de

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

June 30, 2026 | globenewswire.com

Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) - Share Price and Research

June 24, 2026 | intelligentinvestor.com.auI

Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome

June 23, 2026 | globenewswire.com

Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003

June 18, 2026 | globenewswire.com

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

June 16, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GRTS, CALC, INTS, and QNRX Company Descriptions

CalciMedica NASDAQ:CALC

$2.17 -0.03 (-1.36%)

As of 09/4/2026 04:00 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Gritstone bio NASDAQ:GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Intensity Therapeutics NASDAQ:INTS

$4.10 +0.10 (+2.50%)

As of 09/4/2026 04:00 PM Eastern

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Quoin Pharmaceuticals NASDAQ:QNRX

$7.26 -0.61 (-7.75%)

As of 09/4/2026 04:00 PM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRTS, CALC, INTS, and QNRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRTS, CALC, INTS, and QNRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRTS, CALC, INTS, and QNRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GRTS, CALC, INTS, and QNRX Company Descriptions

CalciMedica NASDAQ:CALC

Gritstone bio NASDAQ:GRTS

Intensity Therapeutics NASDAQ:INTS

Quoin Pharmaceuticals NASDAQ:QNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRTS, CALC, INTS, and QNRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRTS, CALC, INTS, and QNRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRTS, CALC, INTS, and QNRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GRTS, CALC, INTS, and QNRX Company Descriptions

CalciMedica NASDAQ:CALC

Gritstone bio NASDAQ:GRTS

Intensity Therapeutics NASDAQ:INTS

Quoin Pharmaceuticals NASDAQ:QNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools